Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Tislelizumab, an anti‐programmed death protein‐1 (PD‐1) monoclonal antibody, was engineered to minimize binding to the FcγR on macrophages to abrogate antibody‐dependent phagocytosis, a mechanism of T‐cell clearance and potential resistance to anti‐PD‐1 therapy. This single‐arm phase 2 trial (NCT040...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Sci
Glavni autori: Ye, Dingwei, Liu, Jiyan, Zhou, Aiping, Zou, Qing, Li, Hanzhong, Fu, Cheng, Hu, Hailong, Huang, Jian, Zhu, Shaoxing, Jin, Jie, Ma, Lulin, Guo, Jianming, Xiao, Jun, Park, Se Hoon, Zhang, Dahong, Qiu, Xiusong, Bao, Yuanyuan, Zhang, Lilin, Shen, Wei, Bi, Feng
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7780053/
https://ncbi.nlm.nih.gov/pubmed/33047430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14681
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items